AbbVie (NYSE:ABBV) has agreed to acquire all outstanding equity of neuroscience-focused biotech Aliada Therapeutics for $1.4B ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

The acquisition will allow AbbVie to accelerate development of ALIA-1758, a potential disease-modifying therapy for Alzheimer ...

With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...

Welcome to the AbbVie third quarter 2024 earnings conference call. [Operator instructions] I would now like to introduce Ms.

AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...

AbbVie has announced that it will be acquiring Aliada Therapeutics for $1.4bn, marking a notable boost to its neuroscience ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...

AbbVie to acquire biotechnology company, Aliada Therapeutics for $1.4 billion: North Chicago, Illinois Wednesday, October 30, 2024, 09:00 Hrs [IST] AbbVie, an American pharmaceuti ...